LYEL MEXC RealStocks
Own real LYEL shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 05:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lyell Immunopharma, Inc. (LYEL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.60, with a market capitalization of $411.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.20 to $45.00. This page covers its latest market performance, valuation, price trends and company information.
$411.81M | |
$16.70 | |
$16.86 | |
$15.49 | |
$16.86 | |
109.86K | |
173.02K | |
-- | |
$45.00 | |
$7.20 | |
-- | |
-- |
Lyell Immunopharma, Inc. (LYEL) last closed at $15.60 as of 2026-11-12 23:54:00, down 7.24% ($1.22) from the previous close of $16.86.
During the latest regular trading session, LYEL traded between $15.49 and $16.86, with a volume of 109.86K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Lyell Immunopharma, Inc. (LYEL) moved from $10.77 to $15.60, representing a gain of 44.88% ($4.83).
The stock traded between $10.58 and $17.61 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 411.50 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.2%
LYEL is currently trading at $15.60, placing it 22.2% of the way from its 52-week low of $7.20 to its 52-week high of $45.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 161 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Lyell Immunopharma, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Lyell Immunopharma, Inc. (LYEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LYEL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LYEL shares and USD.
LYEL Shares to USD
1.00 LYEL shares = 15.604 USD
Calculations are estimates based on the latest available price and are for reference only.